Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Kempharm Inc (KMPH)

Kempharm Inc (KMPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 193,856
  • Shares Outstanding, K 34,494
  • Annual Sales, $ 28,650 K
  • Annual Income, $ -8,560 K
  • 60-Month Beta 2.82
  • Price/Sales 6.45
  • Price/Cash Flow 21.48
  • Price/Book 1.86
Trade KMPH with:

Options Overview Details

View History
  • Implied Volatility 108.16% ( -21.37%)
  • Historical Volatility 62.54%
  • IV Percentile 42%
  • IV Rank 21.04%
  • IV High 255.21% on 06/16/22
  • IV Low 68.99% on 06/06/22
  • Put/Call Vol Ratio 3.19
  • Today's Volume 1,959
  • Volume Avg (30-Day) 450
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 42,625
  • Open Int (30-Day) 41,665

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.16
  • Low Estimate -0.17
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -183.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.14 +8.37%
on 07/26/22
6.63 -15.99%
on 08/11/22
+0.12 (+2.20%)
since 07/19/22
3-Month
4.03 +38.21%
on 06/16/22
6.63 -15.99%
on 08/11/22
+0.46 (+9.00%)
since 05/19/22
52-Week
4.00 +39.25%
on 05/12/22
10.80 -48.42%
on 10/22/21
-3.33 (-37.42%)
since 08/19/21

Most Recent Stories

More News
Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

DERM : 3.38 (-7.65%)
KMPH : 5.57 (-0.89%)
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

CELEBRATION, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company...

KMPH : 5.57 (-0.89%)
CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CTIC : 5.70 (+1.97%)
KMPH : 5.57 (-0.89%)
Lyell Immunopharma (LYEL) Reports Q2 Loss, Tops Revenue Estimates

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 51.61% and 960.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LYEL : 7.04 (-4.35%)
KMPH : 5.57 (-0.89%)
KemPharm to Report Second Quarter 2022 Financial Results

CELEBRATION, Fla., Aug. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company...

KMPH : 5.57 (-0.89%)
KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference

CELEBRATION, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company...

KMPH : 5.57 (-0.89%)
KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting

CELEBRATION, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company...

KMPH : 5.57 (-0.89%)
Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?

Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the...

ACRS : 16.53 (+0.98%)
KMPH : 5.57 (-0.89%)
KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion

Three clinical studies demonstrated serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), yielded significantly lower abuse-related...

KMPH : 5.57 (-0.89%)
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M

KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.

KMPH : 5.57 (-0.89%)
ACRS : 16.53 (+0.98%)
SLNO : 0.1720 (-1.77%)
VRCA : 3.40 (-9.09%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Business Summary

KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303...

See More

Key Turning Points

3rd Resistance Point 5.75
2nd Resistance Point 5.66
1st Resistance Point 5.62
Last Price 5.57
1st Support Level 5.49
2nd Support Level 5.40
3rd Support Level 5.36

See More

52-Week High 10.80
Fibonacci 61.8% 8.20
Fibonacci 50% 7.40
Fibonacci 38.2% 6.60
Last Price 5.57
52-Week Low 4.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar